Xenon Pharmaceuticals Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
XENE$40.45+3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
(Expressed in thousands of U.S. dollars except share amounts)
| Common shares · Additionalpaid-incapital · Accumulateddeficit · Accumulated other comprehensiveincome (loss) · Totalshareholders'equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2022 | 62,587,701 | $1,065,136 | $142,108 | $(482,747) | $(3,000) | 721,497 |
| Net loss for the year | — | — | — | (182,393) | — | (182,393) |
| Issuance of common shares and pre-funded warrants, net | 10,701,842 | 330,010 | 23,477 | — | — | 353,487 |
| Exercise of pre-funded warrants | 1,700,000 | 35,913 | (35,913) | — | — | — |
| Stock-based compensation expense | — | — | 32,372 | — | — | 32,372 |
| Issuance of common shares pursuant to equity incentive plans | 381,434 | 5,315 | (5,280) | — | — | 35 |
| Other comprehensive income | — | — | — | — | 2,923 | 2,923 |
| Balance as of December 31, 2023 | 75,370,977 | $1,436,374 | $156,764 | $(665,140) | $(77) | 927,921 |
| Net loss for the year | — | — | — | (234,330) | — | (234,330) |
| Issuance of common shares, net | 310,000 | 12,083 | — | — | — | 12,083 |
| Stock-based compensation expense | — | — | 50,717 | — | — | 50,717 |
| Issuance of common shares pursuant to equity incentive plans | 735,109 | 8,379 | (8,332) | — | — | 47 |
| Other comprehensive loss | — | — | — | — | (1,535) | (1,535) |
| Balance as of December 31, 2024 | 76,416,086 | $1,456,836 | $199,149 | $(899,470) | $(1,612) | 754,903 |
| Net loss for the year | — | — | — | (345,910) | — | (345,910) |
| Issuance of common shares, net | 2,651,023 | 112,151 | — | — | — | 112,151 |
| Exercise of warrant | 30,792 | 291 | (291) | — | — | — |
| Stock-based compensation expense | — | — | 53,707 | — | — | 53,707 |
| Issuance of common shares pursuant to equity incentive plans | 912,889 | 29,293 | (24,331) | — | — | 4,962 |
| Other comprehensive income | — | — | — | — | 1,947 | 1,947 |
| Balance as of December 31, 2025 | 80,010,790 | $1,598,571 | $228,234 | $(1,245,380) | $335 | 581,760 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.